Hoth Therapeutics' GDNF Shows Superior Efficacy Over Semaglutide in Preclinical Obesity Study
Key Insights
Hoth Therapeutics revealed preclinical data showing GDNF (search) outperformed semaglutide in weight stabilization, glucose tolerance, and liver weight reduction in female mouse models.
GDNF (search) attenuated weight gain by 10-15% in female mice on high-fat diets while semaglutide showed no significant impact in the same population.
The company positions GDNF (search) as a potential game-changer in the $200 billion obesity market, offering differentiated mechanisms to address GLP-1 agonist limitations.
Hoth Therapeutics Inc. (NASDAQ:HOTH) announced preclinical data demonstrating that its experimental obesity treatment, glial cell-derived neurotrophic factor (GDNF (search)), outperformed semaglutide across multiple efficacy measures in head-to-head comparisons. The U.S. Veterans Administration-backed study builds on prior research showing GDNF's protective role against diet-induced obesity and positions the compound as a potential alternative to current GLP-1 agonists in the obesity treatment landscape.
Superior Performance in Female Models
In female mice maintained on a high-fat Western diet, GDNF (search) demonstrated superior efficacy compared to semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic. GDNF attenuated weight gain by 10-15%, leading to a plateau in the final weeks of treatment, while semaglutide showed no significant impact in the same population. Researchers noted that higher doses or longer treatment durations could amplify GDNF's effects, suggesting even greater potential for sustained weight loss.
The metabolic benefits extended beyond weight control. GDNF (search) fully normalized fasting glucose and improved overall response to glucose challenges, outperforming semaglutide in females. Baseline improvements were also observed in males, indicating broad metabolic benefits across both sexes.
Liver and Adipose Tissue Benefits
GDNF (search) demonstrated significant hepatic benefits, reducing liver weight by 20-30% and preventing adipose tissue accumulation in females, surpassing semaglutide's effects in these measures. These findings are particularly relevant given that metabolic-associated steatotic liver disease (MASLD) impacts up to 30% of adults globally.
Market Positioning and Differentiated Mechanism
The company exclusively told Benzinga that the update positions GDNF (search) as a potential game-changer in the $200 billion obesity market. GDNF offers a differentiated mechanism that could address limitations of current GLP-1 agonists, including gastrointestinal side effects and muscle loss. With obesity affecting over 1 billion people globally, GDNF's multi-faceted benefits could revolutionize treatment paradigms.
Development Timeline and Pipeline Context
Future analyses will include liver pathology, lipid content, and gene/protein expression studies to further elucidate GDNF (search)'s mechanisms of action. Hoth plans to accelerate GDNF toward IND-enabling studies, targeting clinical trials in 2027.
The GDNF (search) program represents part of Hoth's broader pipeline, which includes HT-001 in Phase 2 for cancer-related skin toxicities, HT-KIT with Orphan Drug Designation for mast cell cancers, and HT-ALZ for Alzheimer's disease. In January, the company reported that 100% of evaluable patients in the open-label pharmacokinetic cohort of its ongoing CLEER-001 trial evaluating HT-001 achieved clinical response by Week 6, with an approximate 50% reduction in investigator-assessed disease severity from baseline.